These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 27713349)

  • 41.
    Pellati F; Borgonetti V; Brighenti V; Biagi M; Benvenuti S; Corsi L
    Biomed Res Int; 2018; 2018():1691428. PubMed ID: 30627539
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Role of Cannabidiol (CBD) in Chronic Pain Management: An Assessment of Current Evidence.
    Boyaji S; Merkow J; Elman RNM; Kaye AD; Yong RJ; Urman RD
    Curr Pain Headache Rep; 2020 Jan; 24(2):4. PubMed ID: 31980957
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Even High Doses of Oral Cannabidol Do Not Cause THC-Like Effects in Humans: Comment on Merrick et al.
    Grotenhermen F; Russo E; Zuardi AW
    Cannabis Cannabinoid Res; 2017; 2(1):1-4. PubMed ID: 28861499
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adenosine A
    Aso E; Fernández-Dueñas V; López-Cano M; Taura J; Watanabe M; Ferrer I; Luján R; Ciruela F
    Mol Neurobiol; 2019 Aug; 56(8):5382-5391. PubMed ID: 30610611
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
    Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance.
    Hayakawa K; Mishima K; Nozako M; Ogata A; Hazekawa M; Liu AX; Fujioka M; Abe K; Hasebe N; Egashira N; Iwasaki K; Fujiwara M
    Neuropharmacology; 2007 Mar; 52(4):1079-87. PubMed ID: 17320118
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors.
    Mecha M; Feliú A; Iñigo PM; Mestre L; Carrillo-Salinas FJ; Guaza C
    Neurobiol Dis; 2013 Nov; 59():141-50. PubMed ID: 23851307
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats.
    Parker LA; Burton P; Sorge RE; Yakiwchuk C; Mechoulam R
    Psychopharmacology (Berl); 2004 Sep; 175(3):360-6. PubMed ID: 15138755
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice.
    Aso E; Sánchez-Pla A; Vegas-Lozano E; Maldonado R; Ferrer I
    J Alzheimers Dis; 2015; 43(3):977-91. PubMed ID: 25125475
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A systematic review of the antipsychotic properties of cannabidiol in humans.
    Iseger TA; Bossong MG
    Schizophr Res; 2015 Mar; 162(1-3):153-61. PubMed ID: 25667194
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice.
    Gomes FV; Del Bel EA; Guimarães FS
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():43-7. PubMed ID: 23791616
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differential effects of cannabis extracts and pure plant cannabinoids on hippocampal neurones and glia.
    Ryan D; Drysdale AJ; Pertwee RG; Platt B
    Neurosci Lett; 2006 Nov; 408(3):236-41. PubMed ID: 16997463
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Heat exposure of Cannabis sativa extracts affects the pharmacokinetic and metabolic profile in healthy male subjects.
    Eichler M; Spinedi L; Unfer-Grauwiler S; Bodmer M; Surber C; Luedi M; Drewe J
    Planta Med; 2012 May; 78(7):686-91. PubMed ID: 22411724
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Acute effects of Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity.
    Juckel G; Roser P; Nadulski T; Stadelmann AM; Gallinat J
    Schizophr Res; 2007 Dec; 97(1-3):109-17. PubMed ID: 17884351
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interactions between THC and cannabidiol in mouse models of cannabinoid activity.
    Varvel SA; Wiley JL; Yang R; Bridgen DT; Long K; Lichtman AH; Martin BR
    Psychopharmacology (Berl); 2006 Jun; 186(2):226-34. PubMed ID: 16572263
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
    Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 3H-delta 9-Tetrahydrocannabinol, 3H-cannabinol and 3H-cannabidiol: penetration and regional distribution in rat brain.
    Alozie SO; Martin BR; Harris LS; Dewey WL
    Pharmacol Biochem Behav; 1980 Feb; 12(2):217-21. PubMed ID: 6246544
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review.
    Bartoli F; Riboldi I; Bachi B; Calabrese A; Moretti F; Crocamo C; Carrà G
    J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33810033
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol.
    Russo E; Guy GW
    Med Hypotheses; 2006; 66(2):234-46. PubMed ID: 16209908
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interactions between cannabidiol and Δ
    Todd SM; Zhou C; Clarke DJ; Chohan TW; Bahceci D; Arnold JC
    Eur Neuropsychopharmacol; 2017 Feb; 27(2):132-145. PubMed ID: 28043732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.